Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
Department of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan.
World J Surg. 2021 Aug;45(8):2513-2520. doi: 10.1007/s00268-021-06138-9. Epub 2021 May 1.
The presence of chronic inflammation and nutritional status in cancer patients affects its prognosis. There is a clinical need for a prognostic predictor that is objective and accurate, and that can be easily evaluated by preoperative screening. We evaluated the importance and usefulness of the preoperative modified systemic inflammation score (mSIS) to predict the long-term outcome of patients undergoing curative resection for gastric cancer (GC).
Of the 3571 patients who underwent curative resection for GC in nine institutions between January 2010 and December 2014, 1764 patients who met the inclusion criteria were included. The mSIS was formulated according to the serum albumin level (ALB) and lymphocyte-to-monocyte ratio (LMR) as follows: mSIS 0 (ALB ≥ 4.0 g/dL and LMR ≥ 3.4), mSIS 1 (ALB < 4.0 g/dL or LMR < 3.4), and mSIS 2 (ALB < 4.0 g/dL and LMR < 3.4).
Patients were categorized into preoperative mSIS 0 (n = 955), mSIS 1 (n = 584), and mSIS 2 (n = 225) groups. The overall survival times and the disease-free survival times of patients in preoperative mSIS 0,1 and 2 sequentially shortened (P < 0.0001), and mSIS 1 and 2 were identified as an independent prognostic factor (hazard ratio [HR] 1.35, 95% confidence interval [CI] 1.06-1.272, P = 0.0125 and HR 1.63, 95% CI 1.21-2.19, P = 0.0012). A stepwise increase in the prevalence of hematogenous recurrences was directly proportional to the mSIS. A forest plot revealed that mSIS 0,1 was associated with a greater risk of overall survival in most subgroups.
Preoperative mSIS can be easily calculated, and it is suggested that it is useful as a prognostic predictor of patients with different disease stages, for stratifying and evaluating clinical outcomes.
癌症患者的慢性炎症和营养状况会影响其预后。目前需要一种客观、准确且易于通过术前筛查评估的预后预测指标。我们评估了术前改良全身炎症评分(mSIS)对预测接受根治性胃切除术(GC)的患者长期结局的重要性和实用性。
在 2010 年 1 月至 2014 年 12 月期间,在 9 家机构接受根治性 GC 切除术的 3571 例患者中,纳入了符合纳入标准的 1764 例患者。mSIS 根据血清白蛋白水平(ALB)和淋巴细胞与单核细胞比值(LMR)制定,公式如下:mSIS 0(ALB≥4.0 g/dL 和 LMR≥3.4)、mSIS 1(ALB<4.0 g/dL 或 LMR<3.4)和 mSIS 2(ALB<4.0 g/dL 和 LMR<3.4)。
患者分为术前 mSIS 0(n=955)、mSIS 1(n=584)和 mSIS 2(n=225)组。mSIS 0、1 和 2 组患者的总生存时间和无病生存时间依次缩短(P<0.0001),mSIS 1 和 2 被确定为独立的预后因素(风险比[HR]1.35,95%置信区间[CI]1.06-1.272,P=0.0125 和 HR 1.63,95%CI 1.21-2.19,P=0.0012)。血液复发的患病率呈阶梯式增加,与 mSIS 直接成正比。森林图显示,mSIS 0、1 与大多数亚组的总生存风险增加相关。
术前 mSIS 易于计算,建议其作为不同疾病阶段患者的预后预测指标具有一定价值,可用于分层和评估临床结局。